Genome Editing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, Others), By Deliver Mode (Ex-vivo, In-vivo), By Application (Genetic Engineering, Clinical Applications), By Mode (Contract, In-house), By End User (Biotechnology and pharmaceutical companies, Academic and government research institutes, Contract research organizations), By Region & Competition, 2021-2031F
The Global Genome Editing Market is projected to experience substantial growth, increasing from a valuation of USD 9.39 Billion in 2025 to USD 23.66 Billion by 2031, representing a CAGR of 16.65%. Genome editing involves a range of technologies that allow scientists to modify an organism's DNA by adding, removing, or altering genetic material at specific sites. The primary drivers behind this expansion include the growing prevalence of cancer and genetic disorders worldwide, coupled with significant capital investment in biotechnology research. This momentum is highlighted by recent industry achievements; according to the Alliance for Regenerative Medicine, the cell and gene therapy sector secured a record nine global regulatory approvals in 2024, confirming the clinical viability of these advanced therapies and boosting investor confidence.
Despite these advancements, the market faces notable challenges related to safety and ethical concerns. The potential for off-target effects, where unintended genetic modifications occur, serves as a major technical barrier that complicates the regulatory process. Consequently, manufacturers must adhere to strict compliance standards and navigate extended development timelines. These hurdles increase operational burdens and may slow the pace at which new genome editing products enter the commercial market and achieve widespread adoption.
Market Driver
Rising public and private funding for genomic research serves as a major catalyst for the market, facilitating the translation of theoretical gene editing concepts into viable clinical therapies. This influx of capital enables biotechnology firms to support the capital-intensive research and development necessary for next-generation in vivo treatments. For example, large venture capital rounds are validating the potential of novel engineering platforms and targeted delivery systems. As noted in the 'Capstan Therapeutics Announces $175M Series B Financing' press release from March 2024, Capstan Therapeutics raised $175 million to advance its in vivo chimeric antigen receptor T cell candidate for autoimmune disorders. Such investments demonstrate strong market confidence in resolving the delivery challenges essential for commercial scalability.
Simultaneously, rapid advancements in CRISPR and next-generation technologies are broadening the therapeutic scope beyond hereditary cancers to cover a wider range of indications. Developers are utilizing precise base editing techniques and novel enzymes to treat complex conditions while minimizing off-target risks. This technological evolution is evident in the diversification of clinical pipelines; according to the American Society of Gene & Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q3 2024 Report' published in October 2024, 51% of new gene therapy trials focused on non-oncology indications. Furthermore, leading market players maintain robust financial health to sustain innovation, with CRISPR Therapeutics reporting a cash position of approximately $1.9 billion in 2024.
Market Challenge
The inherent risk of off-target effects remains a significant safety barrier that restricts the growth of the global genome editing market. Since unintended genetic alterations can lead to severe long-term health issues, such as oncogenesis, regulatory bodies enforce increasingly rigorous compliance standards. These safety concerns necessitate extensive preclinical validation and prolonged patient monitoring, which significantly extends development timelines. Consequently, companies face escalating operational costs and delays in transitioning candidates from research to human testing, creating a bottleneck in the commercial pipeline that discourages rapid market entry.
This regulatory slowdown is reflected in recent industry activity. According to the American Society of Gene & Cell Therapy, the sector experienced a decline in development velocity during the third quarter of 2025, with only 125 new clinical trials initiated globally. This contraction highlights how the complexity of meeting safety thresholds for precise genetic modification limits the volume of new therapies advancing to clinical stages. By necessitating a more cautious and protracted development approach, these technical and safety hurdles effectively dampen the rate at which new products can reach the market.
Market Trends
The integration of artificial intelligence into precision design is fundamentally transforming the genome editing landscape. Moving beyond traditional methods that rely on mining bacterial databases, generative AI models are now creating synthetic editing systems with superior specificity. This computational approach directly tackles the challenge of off-target effects by predicting and minimizing unintended edits before laboratory validation. A significant breakthrough occurred when Profluent announced in their April 2024 press release, 'Editing the Human Genome with AI', that their AI-generated OpenCRISPR-1 system achieved a 95% reduction in off-target editing compared to the standard SpCas9 enzyme, demonstrating the potential of machine learning to enhance therapeutic safety.
Concurrently, the market is seeing the rapid commercialization of gene-edited agricultural crops, extending the industry's influence beyond human therapeutics to global food security. Agricultural biotechnology developers are applying CRISPR technologies to create crops that are resilient to climate change and offer improved traits, moving from experimental trials to retail markets. This sector is also experiencing strategic consolidation as major agricultural companies partner with specialized editing firms. For instance, according to a September 2024 press release titled 'Pairwise Partners with Corteva', Pairwise secured a $25 million equity investment from Corteva to accelerate the development of sustainable agricultural solutions, signaling strong industrial confidence in non-therapeutic applications.
Key Market Players
In this report, the Global Genome Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Genome Editing Market.
Available Customizations:
Global Genome Editing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Despite these advancements, the market faces notable challenges related to safety and ethical concerns. The potential for off-target effects, where unintended genetic modifications occur, serves as a major technical barrier that complicates the regulatory process. Consequently, manufacturers must adhere to strict compliance standards and navigate extended development timelines. These hurdles increase operational burdens and may slow the pace at which new genome editing products enter the commercial market and achieve widespread adoption.
Market Driver
Rising public and private funding for genomic research serves as a major catalyst for the market, facilitating the translation of theoretical gene editing concepts into viable clinical therapies. This influx of capital enables biotechnology firms to support the capital-intensive research and development necessary for next-generation in vivo treatments. For example, large venture capital rounds are validating the potential of novel engineering platforms and targeted delivery systems. As noted in the 'Capstan Therapeutics Announces $175M Series B Financing' press release from March 2024, Capstan Therapeutics raised $175 million to advance its in vivo chimeric antigen receptor T cell candidate for autoimmune disorders. Such investments demonstrate strong market confidence in resolving the delivery challenges essential for commercial scalability.
Simultaneously, rapid advancements in CRISPR and next-generation technologies are broadening the therapeutic scope beyond hereditary cancers to cover a wider range of indications. Developers are utilizing precise base editing techniques and novel enzymes to treat complex conditions while minimizing off-target risks. This technological evolution is evident in the diversification of clinical pipelines; according to the American Society of Gene & Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q3 2024 Report' published in October 2024, 51% of new gene therapy trials focused on non-oncology indications. Furthermore, leading market players maintain robust financial health to sustain innovation, with CRISPR Therapeutics reporting a cash position of approximately $1.9 billion in 2024.
Market Challenge
The inherent risk of off-target effects remains a significant safety barrier that restricts the growth of the global genome editing market. Since unintended genetic alterations can lead to severe long-term health issues, such as oncogenesis, regulatory bodies enforce increasingly rigorous compliance standards. These safety concerns necessitate extensive preclinical validation and prolonged patient monitoring, which significantly extends development timelines. Consequently, companies face escalating operational costs and delays in transitioning candidates from research to human testing, creating a bottleneck in the commercial pipeline that discourages rapid market entry.
This regulatory slowdown is reflected in recent industry activity. According to the American Society of Gene & Cell Therapy, the sector experienced a decline in development velocity during the third quarter of 2025, with only 125 new clinical trials initiated globally. This contraction highlights how the complexity of meeting safety thresholds for precise genetic modification limits the volume of new therapies advancing to clinical stages. By necessitating a more cautious and protracted development approach, these technical and safety hurdles effectively dampen the rate at which new products can reach the market.
Market Trends
The integration of artificial intelligence into precision design is fundamentally transforming the genome editing landscape. Moving beyond traditional methods that rely on mining bacterial databases, generative AI models are now creating synthetic editing systems with superior specificity. This computational approach directly tackles the challenge of off-target effects by predicting and minimizing unintended edits before laboratory validation. A significant breakthrough occurred when Profluent announced in their April 2024 press release, 'Editing the Human Genome with AI', that their AI-generated OpenCRISPR-1 system achieved a 95% reduction in off-target editing compared to the standard SpCas9 enzyme, demonstrating the potential of machine learning to enhance therapeutic safety.
Concurrently, the market is seeing the rapid commercialization of gene-edited agricultural crops, extending the industry's influence beyond human therapeutics to global food security. Agricultural biotechnology developers are applying CRISPR technologies to create crops that are resilient to climate change and offer improved traits, moving from experimental trials to retail markets. This sector is also experiencing strategic consolidation as major agricultural companies partner with specialized editing firms. For instance, according to a September 2024 press release titled 'Pairwise Partners with Corteva', Pairwise secured a $25 million equity investment from Corteva to accelerate the development of sustainable agricultural solutions, signaling strong industrial confidence in non-therapeutic applications.
Key Market Players
- Cibus Inc
- Recombinetics, Inc
- Merck & Co., Inc
- Sangamo Therapeutics Inc
- Editas Medicine Inc
- Precision BioSciences Inc
- CRISPR Therapeutics Inc
- Intellia Therapeutics, Inc
- Caribou Biosciences, Inc
- Takara Bio Inc
In this report, the Global Genome Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Genome Editing Market, By Technology
- (CRISPR)/Cas9
- TALENs/MegaTALs
- ZFN
- Meganuclease
- Others
- Genome Editing Market, By Deliver Mode
- Ex-vivo
- In-vivo
- Genome Editing Market, By Application
- Genetic Engineering
- Clinical Applications
- Genome Editing Market, By Mode
- Contract
- In-house
- Genome Editing Market, By End User
- Biotechnology and pharmaceutical companies
- Academic and government research institutes
- Contract research organizations
- Genome Editing Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Genome Editing Market.
Available Customizations:
Global Genome Editing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOME EDITING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, Others)
5.2.2. By Deliver Mode (Ex-vivo, In-vivo)
5.2.3. By Application (Genetic Engineering, Clinical Applications)
5.2.4. By Mode (Contract, In-house)
5.2.5. By End User (Biotechnology and pharmaceutical companies, Academic and government research institutes, Contract research organizations)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENOME EDITING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Deliver Mode
6.2.3. By Application
6.2.4. By Mode
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Genome Editing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Deliver Mode
6.3.1.2.3. By Application
6.3.1.2.4. By Mode
6.3.1.2.5. By End User
6.3.2. Canada Genome Editing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Deliver Mode
6.3.2.2.3. By Application
6.3.2.2.4. By Mode
6.3.2.2.5. By End User
6.3.3. Mexico Genome Editing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Deliver Mode
6.3.3.2.3. By Application
6.3.3.2.4. By Mode
6.3.3.2.5. By End User
7. EUROPE GENOME EDITING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Deliver Mode
7.2.3. By Application
7.2.4. By Mode
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genome Editing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Deliver Mode
7.3.1.2.3. By Application
7.3.1.2.4. By Mode
7.3.1.2.5. By End User
7.3.2. France Genome Editing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Deliver Mode
7.3.2.2.3. By Application
7.3.2.2.4. By Mode
7.3.2.2.5. By End User
7.3.3. United Kingdom Genome Editing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Deliver Mode
7.3.3.2.3. By Application
7.3.3.2.4. By Mode
7.3.3.2.5. By End User
7.3.4. Italy Genome Editing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Deliver Mode
7.3.4.2.3. By Application
7.3.4.2.4. By Mode
7.3.4.2.5. By End User
7.3.5. Spain Genome Editing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Deliver Mode
7.3.5.2.3. By Application
7.3.5.2.4. By Mode
7.3.5.2.5. By End User
8. ASIA PACIFIC GENOME EDITING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Deliver Mode
8.2.3. By Application
8.2.4. By Mode
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genome Editing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Deliver Mode
8.3.1.2.3. By Application
8.3.1.2.4. By Mode
8.3.1.2.5. By End User
8.3.2. India Genome Editing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Deliver Mode
8.3.2.2.3. By Application
8.3.2.2.4. By Mode
8.3.2.2.5. By End User
8.3.3. Japan Genome Editing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Deliver Mode
8.3.3.2.3. By Application
8.3.3.2.4. By Mode
8.3.3.2.5. By End User
8.3.4. South Korea Genome Editing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Deliver Mode
8.3.4.2.3. By Application
8.3.4.2.4. By Mode
8.3.4.2.5. By End User
8.3.5. Australia Genome Editing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Deliver Mode
8.3.5.2.3. By Application
8.3.5.2.4. By Mode
8.3.5.2.5. By End User
9. MIDDLE EAST & AFRICA GENOME EDITING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Deliver Mode
9.2.3. By Application
9.2.4. By Mode
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genome Editing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Deliver Mode
9.3.1.2.3. By Application
9.3.1.2.4. By Mode
9.3.1.2.5. By End User
9.3.2. UAE Genome Editing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Deliver Mode
9.3.2.2.3. By Application
9.3.2.2.4. By Mode
9.3.2.2.5. By End User
9.3.3. South Africa Genome Editing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Deliver Mode
9.3.3.2.3. By Application
9.3.3.2.4. By Mode
9.3.3.2.5. By End User
10. SOUTH AMERICA GENOME EDITING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Deliver Mode
10.2.3. By Application
10.2.4. By Mode
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genome Editing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Deliver Mode
10.3.1.2.3. By Application
10.3.1.2.4. By Mode
10.3.1.2.5. By End User
10.3.2. Colombia Genome Editing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Deliver Mode
10.3.2.2.3. By Application
10.3.2.2.4. By Mode
10.3.2.2.5. By End User
10.3.3. Argentina Genome Editing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Deliver Mode
10.3.3.2.3. By Application
10.3.3.2.4. By Mode
10.3.3.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENOME EDITING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Cibus Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Recombinetics, Inc
15.3. Merck & Co., Inc
15.4. Sangamo Therapeutics Inc
15.5. Editas Medicine Inc
15.6. Precision BioSciences Inc
15.7. CRISPR Therapeutics Inc
15.8. Intellia Therapeutics, Inc
15.9. Caribou Biosciences, Inc
15.10. Takara Bio Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENOME EDITING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, Others)
5.2.2. By Deliver Mode (Ex-vivo, In-vivo)
5.2.3. By Application (Genetic Engineering, Clinical Applications)
5.2.4. By Mode (Contract, In-house)
5.2.5. By End User (Biotechnology and pharmaceutical companies, Academic and government research institutes, Contract research organizations)
5.2.6. By Region
5.2.7. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENOME EDITING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Deliver Mode
6.2.3. By Application
6.2.4. By Mode
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Genome Editing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Deliver Mode
6.3.1.2.3. By Application
6.3.1.2.4. By Mode
6.3.1.2.5. By End User
6.3.2. Canada Genome Editing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Deliver Mode
6.3.2.2.3. By Application
6.3.2.2.4. By Mode
6.3.2.2.5. By End User
6.3.3. Mexico Genome Editing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Deliver Mode
6.3.3.2.3. By Application
6.3.3.2.4. By Mode
6.3.3.2.5. By End User
7. EUROPE GENOME EDITING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Deliver Mode
7.2.3. By Application
7.2.4. By Mode
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Genome Editing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Deliver Mode
7.3.1.2.3. By Application
7.3.1.2.4. By Mode
7.3.1.2.5. By End User
7.3.2. France Genome Editing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Deliver Mode
7.3.2.2.3. By Application
7.3.2.2.4. By Mode
7.3.2.2.5. By End User
7.3.3. United Kingdom Genome Editing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Deliver Mode
7.3.3.2.3. By Application
7.3.3.2.4. By Mode
7.3.3.2.5. By End User
7.3.4. Italy Genome Editing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Deliver Mode
7.3.4.2.3. By Application
7.3.4.2.4. By Mode
7.3.4.2.5. By End User
7.3.5. Spain Genome Editing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Deliver Mode
7.3.5.2.3. By Application
7.3.5.2.4. By Mode
7.3.5.2.5. By End User
8. ASIA PACIFIC GENOME EDITING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Deliver Mode
8.2.3. By Application
8.2.4. By Mode
8.2.5. By End User
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Genome Editing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Deliver Mode
8.3.1.2.3. By Application
8.3.1.2.4. By Mode
8.3.1.2.5. By End User
8.3.2. India Genome Editing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Deliver Mode
8.3.2.2.3. By Application
8.3.2.2.4. By Mode
8.3.2.2.5. By End User
8.3.3. Japan Genome Editing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Deliver Mode
8.3.3.2.3. By Application
8.3.3.2.4. By Mode
8.3.3.2.5. By End User
8.3.4. South Korea Genome Editing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Deliver Mode
8.3.4.2.3. By Application
8.3.4.2.4. By Mode
8.3.4.2.5. By End User
8.3.5. Australia Genome Editing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Deliver Mode
8.3.5.2.3. By Application
8.3.5.2.4. By Mode
8.3.5.2.5. By End User
9. MIDDLE EAST & AFRICA GENOME EDITING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Deliver Mode
9.2.3. By Application
9.2.4. By Mode
9.2.5. By End User
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Genome Editing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Deliver Mode
9.3.1.2.3. By Application
9.3.1.2.4. By Mode
9.3.1.2.5. By End User
9.3.2. UAE Genome Editing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Deliver Mode
9.3.2.2.3. By Application
9.3.2.2.4. By Mode
9.3.2.2.5. By End User
9.3.3. South Africa Genome Editing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Deliver Mode
9.3.3.2.3. By Application
9.3.3.2.4. By Mode
9.3.3.2.5. By End User
10. SOUTH AMERICA GENOME EDITING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Deliver Mode
10.2.3. By Application
10.2.4. By Mode
10.2.5. By End User
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Genome Editing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Deliver Mode
10.3.1.2.3. By Application
10.3.1.2.4. By Mode
10.3.1.2.5. By End User
10.3.2. Colombia Genome Editing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Deliver Mode
10.3.2.2.3. By Application
10.3.2.2.4. By Mode
10.3.2.2.5. By End User
10.3.3. Argentina Genome Editing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Deliver Mode
10.3.3.2.3. By Application
10.3.3.2.4. By Mode
10.3.3.2.5. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENOME EDITING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Cibus Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Recombinetics, Inc
15.3. Merck & Co., Inc
15.4. Sangamo Therapeutics Inc
15.5. Editas Medicine Inc
15.6. Precision BioSciences Inc
15.7. CRISPR Therapeutics Inc
15.8. Intellia Therapeutics, Inc
15.9. Caribou Biosciences, Inc
15.10. Takara Bio Inc
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
